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Ania B. Kawiecki, Helvio Astete, Robert D. Hontz, Chris M. Barker, Gonzalo M. Vazquez-Prokopec,
Amy C. Morrison, Thomas W. Scott, John P. Elder, Alan L. Rothman, Valerie A. Paz-Soldan

Measuring heterogeneity of dengue illness is necessary
to define suitable endpoints in dengue vaccine and therapeutic trials and will help clarify behavioral responses
to illness. To quantify heterogeneity in dengue illness, including milder cases, we developed the Dengue Illness
Perceptions Response (IPR) survey, which captured detailed symptom data, including intensity, duration, and
character, and change in routine activities caused by
illness. During 2016–2019, we collected IPR data daily
during the acute phase of illness for 79 persons with
a positive reverse transcription PCR result for dengue
virus RNA. Most participants had mild ambulatory disease. However, we measured substantial heterogeneity
in illness experience, symptom duration, and maximum
reported intensity of individual symptoms. Symptom intensity was a more valuable predicter of major activity
change during dengue illness than symptom presence
or absence alone. These data suggest that the IPR measures clinically useful heterogeneity in dengue illness
experience and its relation to altered human behavior.

D

engue classically presents as an acute febrile illness lasting ≈5 days and accompanied by headache, musculoskeletal pain, and rash (1). A minority
of infected persons show development of plasma
Author affiliations: University of California Davis, Davis, California,
USA (W.H. Elson, A.B. Kawiecki, C.M. Barker, A.C. Morrison,
T.W. Scott); University of Washington School of Medicine, Seattle,
Washington, USA (R.C. Reiner); US Naval Medical Research Unit
No. 6, Lima and Iquitos, Peru (C. Siles, I. Bazan, S. Vilcarromero,
H. Astete, R.D. Hontz, A.C. Morrison); University of Sussex,
Brighton, UK (A.R. Riley-Powell); Tulane School of Public Health
and Tropical Medicine, New Orleans, Louisiana, USA (A.R. RileyPowell, V.A. Paz-Soldan); Emory University, Atlanta, Georgia,
USA (G.M. Vazquez-Prokopec); San Diego State University, San
Diego, California, USA (J.P. Elder); University of Rhode Island,
Providence, Rhode Island, USA (A.L. Rothman)
DOI: https://doi.org/10.3201/eid2609.191472

leakage syndrome, intravascular volume loss, or
major bleeding, which can lead to shock and death
(2). There are 4 serotypes of dengue (DENV), and
persons show development of long-lasting immunity to the specific serotype after infection. Crossreactive immunity provides short-term protection
against other serotypes. However, under some circumstances, previous infection with a different serotype increases the risk for severe disease (3). The
World Health Organization (WHO) classification
of dengue focuses on distinguishing between mild
cases (classic dengue) and persons with or at risk for
major adverse outcomes or death (severe disease)
(4–6). Moreover, most literature describing the clinical manifestations of dengue evaluates the healthcare-seeking population whose symptoms are likely
to be more severe. DENV infections associated with
milder illness have not been subjected to similar systematic analysis or characterization.
Although the focus on severe disease is an obvious priority, there is value to characterizing the subjective illness experience in persons who have milder
disease. As dengue vaccine development evolves,
one of the challenges will be to accurately measure
the effect of vaccination on the severity of illness.
Measuring the rates of severe disease in vaccine trials is an insensitive approach and addresses only the
small fraction of cases meeting these criteria, leaving
open the possibility that vaccinated persons not meeting the criteria for severe disease had a meaningfully
different disease experience than unvaccinated persons. Behavioral responses and reactions to illness
depend on the illness experience of a person and will
determine whether they attend work or school, selfmedicate, seek medical attention, and move around
their neighborhood, potentially infecting mosquitoes
at other sites (7). Quantifying these relationships will
help identify the human factors essential for virus
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transmission, guide the design of improved control strategies, assist policy makers in assessing the
burden of dengue illness and healthcare needs, and
guide allocation of resources.
As part of a larger epidemiologic study we developed the dengue Illness Perceptions Response (IPR)
survey to gather data to characterize the dengue illness experience of a person, including the range and
intensity of symptoms, and to measure the response
of a person to their illness. We outline the development and application of the IPR, and to illustrate its
potential value, we describe and quantify the heterogeneity of dengue illness and its associations with behavior changes.
Methods
Ethics

The study protocol was approved by the Naval Medical Research Unit No. 6 (NAMRU-6) Institutional
Review Board (IRB) (protocol #NAMRU6.2014.0028)
in compliance with all applicable federal regulations
governing the protection of human subjects. IRB relying agreements were established between NAMRU-6,
the University of California Davis, Tulane University,
Emory University, and the University of California,
San Diego. The protocol was reviewed and approved
by the Loreto Regional Health Department, which
oversees health research in Iquitos.
Field Site

We conducted the study in an established research
unit in the Amazonian city of Iquitos, Peru (7–9).
Based in the department of Loreto, Iquitos has a
population of ≈400,000 and mostly relies on tourism and extractive industries (8,10). More than half
of the population of Loreto depend on government
health insurance, which is available for persons living in poverty (11). Dengue is endemic to Iquitos, and
1 serotype typically dominates at any one time; all 4
DENV serotypes have circulated in Iquitos over the
past 3 decades (8). The force of infection for DENV
in Iquitos was calculated to vary from 0 to 0.33 infections/susceptible person/year during 1999–2010 (12).
In March 2016, Zika virus was detected in Iquitos,
and its transmission dominated for ≈1.5 years (13).
Since 2017, the Asian-American strain of DENV-2 has
been the dominant circulating serotype (A.C. Morrison, unpub. data).
Development of IPR Survey

On the basis of the experience of our team in collecting dengue symptom data and the available
2078

literature, we developed a focus group guide used
to facilitate 6 mixed-sex focus groups to assess how
persons who had recently had dengue illness (or an
adult family member of a child who was infected)
described the experience, including the range, duration, and precise location of symptoms; ways to
describe the severity of the symptoms; and word
choices related to the symptoms. Focus group participants (n = 52) were persons who had laboratoryconfirmed dengue (positive result on DENV reverse
transcription PCR [RT-PCR]) during the previous 3
months and who were recruited by ongoing community or clinic-based febrile illness surveillance.
Using the range of symptoms and descriptions elicited through the focus groups, the research team
developed a first version of the IPR, which was reviewed by collaborating experts and 3 local clinicians experienced in managing dengue to ensure
its medical relevance. These data informed the IPR
development, helping to define the symptoms to be
included and descriptive terms used for symptoms
and determine how to measure symptom intensity
(there was almost unanimous support for scales using facial expressions to grade intensity).
The IPR survey that was implemented collected data on 36 symptoms; depending on the specific
symptom, these data included presence, duration,
intensity, character, frequency and location of symptoms (Appendix Table 1, https://wwwnc.cdc.gov/
EID/article/26/9/19-1472-App1.pdf). We learned
about descriptive terms for various symptoms: musculoskeletal pain was most commonly described as
“beaten up,” affecting the whole body. Headaches
were most commonly described as a “generalized
pressure.” Abdominal pain was most commonly
described as “cramping” and most frequently located in the epigastrium. The survey also asked to
what extent symptoms had affected daily activities:
no change, minor change, or major change. The IPR
was then piloted on 54 persons: 7 children <10 years
of age, 10 persons 10–20 years of age, and 37 persons >20 years of age. Feedback from this pilot testing was used to guide final modifications of the survey; data from these persons are not included in the
main analyses.
Study Design

The study followed a contact-cluster design. Persons
positive for serum DENV RNA by RT-PCR (index caseparticipants) were identified through community- or
clinic-based febrile illness surveillance (7,14). At the
time of blood collection, we administered a retrospective movement survey to the index case-participants
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to identify locations visited in the previous 15 days.
As soon as the initial PCR result was available, usually
the next weekday, persons (contacts) from the home
of the index case-participants and any residential locations visited by the index case-participants were then
invited to provide a blood sample, regardless of the
presence of symptoms; we tested consenting persons
for serum DENV RNA by using RT-PCR. The protocol enabled requesting follow-up samples from PCRnegative contacts at intervals of no less than 2 days;
we tested a median of 2 (interquartile range 2–3) blood
samples from contacts by using PCR.
Index case-participants and any contacts with
positive RT-PCR results (15) for DENV RNA were
invited to respond to a series of surveys relating to
symptoms (IPR), movements throughout the city,
health related qualify of life, and illness-related expenditures. The IPR survey was applied daily (where
possible), starting from the day of the positive RTPCR result until there were no reported symptoms
for 2 days, and then again 30 days later. Inclusion
criteria for the study were an age >5 years, DENV
viremia documented by RT-PCR, and willingness to
provide informed consent or assent for persons 5–17
years of age.
Data Analysis and Statement

We used CommCare (https://www.dimagi.com), an
open-source software platform, to develop a digital
version of the IPR, which we administered by using
handheld tablets (16). Survey data were uploaded to
CommCare secure server where it could be reviewed
by senior project members for discrepancies and corrected if necessary. We forwarded data to a PostgreSQL database (https://www.postgresql.org) and
directly accessed this database and analyzed the data
by using R version 3.5.1 (17). We categorized symptoms into the following clinically defined groups:
constitutional, fever, headache, musculoskeletal, abdominal, cutaneous, respiratory, bleeding, and other
(Appendix Table 2). The final dataset included the
first 14 days of illness for each participant, indicating
for these days symptom intensities from 0 (absence) to
10 (most intense). The survey solicited the maximum
symptom intensity experienced between the day of
collection and either the day the symptom started (in
the first IPR) or the previous survey (in subsequent
IPRs). Intensities recorded in the first IPR were assigned to the first date that the specific symptom was
reported and any gaps in intensity data were imputed
with linear interpolation. For days after the final survey, intensities and frequencies of symptoms were
assumed to be 0. From this dataset we calculated the

duration of illness and of specific symptoms, and the
proportion of symptoms that were reported on each
day of illness. Suspected dengue was defined following the 2009 WHO guidelines as fever and >2 of the
following symptoms: headache, retroorbital pain,
nausea/vomiting, muscle/joint pains, and rash (4).
We performed a correlation analysis of symptom
intensities, excluding imputed intensity values, by
using the cor function in the stats package in R with
use argument as pairwise.complete.observations and
method argument as spearman to generate a correlation matrix and then plotted a heatmap and dendrogram derived from the correlation matrix by using
the pheatmap function in the pheatmap package (18).
To compare index and contact cases, we first compared the mean number of reported symptoms by using a 2-sided Student t-test, and then compared the
proportions of persons reporting specific symptoms
by using the Fisher exact test. Because there were 36
comparisons, we applied a Bonferroni correction to
the α value.
To explore the relationship between major activity change and individual symptom intensity, we performed logistic regression by using the glm function
in the stats package in R, designating major activity
change (present or absent) as the dependent variable
and symptom intensity, age, and sex as independent
variables. To evaluate the benefit of collecting intensity data versus only symptom presence and absence,
we performed 2 logistic regression models for each
symptom by using major activity change as the response variable and either symptom intensity or binary symptom presence as the explanatory variable.
We used the difference in the model Akaike Information Criteria (Δ-AIC) as a means to compare the
2 models, with a positive AIC favoring the use of intensity over presence or absence. All data and R code
used for this analysis are available (https://github.
com/hammoire/dengue_ipr).
Results
We enrolled 79 persons who completed a total of 429
IPR surveys (median 5 surveys/person) (Table 1). A
total of 55 persons were enrolled through febrile illness surveillance (index case-participants), 42 through
community-based surveillance, and 13 through clinicbased surveillance. The remaining 24 persons were enrolled through cluster investigations (contact case-participants); these case-participants were identified from
the total of 408 contacts tested (72% of the 567 eligible
contacts). Index and contact case-participants were
similar in age and sex. The first survey was completed
a median of 3 days after the onset of symptoms (range
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Table 1. Baseline characteristics of participants tested for heterogeneity of dengue illness in community-based prospective study,
Iquitos, Peru*
Characteristic
Total
Index
Contact
No. participants
79
55
24
No. surveys
429
309
120
Sex, no. (%)
M
38 (48)
27 (49)
11 (46)
F
41 (52)
28 (51)
13 (54)
Median age, y (IQR)
17 (12–27.5)
17 (14–26)
14.5 (9.5–31)
Day at diagnosis (IQR)
3 (2–4)
4 (3–5)
2 (1–3)
Serotype, %
DENV-2
76 (96)
53 (96)
23 (96)
DENV-3
3 (4)
2 (4)
1 (4)
WHO suspected dengue† (%)
67 (85)
51 (93)
16 (67)
Warning signs, no. (%)
20 (25)
18 (33)
2 (8)
Hospitalized, no. (%)
7 (9)
6 (11)
1 (4)
*DENV, dengue virus; IQR, interquartile range; WHO, World Health Organization.
†Persons who met the 2009 WHO criteria for suspected dengue (see Methods).

–1 to 8 days). A total of 75% of participants completed
the follow-up survey at a median of 36 days after the
onset of symptoms (range 21–82 days). Seven (9%) participants were hospitalized during the course of their
acute infection (Table 1).
Frequency and Duration of Symptoms

We summarized the overall frequency (Appendix
Figure 1) and duration (Appendix Figure 2) of symptoms. The frequency of individual symptoms did
not differ by sex or age group (younger vs. older
than 18 years of age). All symptoms occurred more
frequently in index case-participants than in contact
case-participants, with the exception of vaginal bleeding. These differences were only significant for bad

taste and chills (p<0.01 with Bonferroni correction)
(Appendix Table 3).
Participants reported a mean symptom duration
of 7.37 days. One person (a contact case-participant)
experienced no symptoms. A total of 5 persons experienced >1 symptoms between the follow-up visit and
the last form in the acute phase of illness, including
nausea (2), malaise (2), headache (1), congestion (1),
itching (1), and fainting (1).
Timing and Characterization of Symptoms

We report the timing of each of 13 symptoms for
which duration data were collected (Figure 1). Malaise preceded other symptoms by 1 day in a substantial fraction of cases and was still reported by >30% of

Figure 1. Timing of 13 key dengue symptoms for participants tested for heterogeneity of dengue illness in community-based prospective
study, Iquitos, Peru. The x-axis represents day of illness and y-axis individual symptoms. Numbers in tiles indicate total number of
persons with a symptom on that day. A total of 79 persons infected with dengue virus participated in surveys.
2080
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Figure 2. Histograms of maximum reported symptom intensities for participants tested for heterogeneity of dengue illness in communitybased prospective study, Iquitos, Peru. Persons who did not report symptoms were excluded. Colors in histograms correspond to
symptom groups defined in Appendix Figure 1 https://wwwnc.cdc.gov/eid/article/26/9/19-1472-App1.pdf. Values for each panel are no.
(%) of participants who reported the specific symptom at any time during their illness. A) malaise, 78 (98.7); B) weakness, 76 (96.2); C)
fever, 74 (93.7); D) chills, 65 (82.3); E) headache, 72 (91.1); F) retroorbital pain, 54 (68.4); G) body pain, 61 (77.2); H) bone pain, 51
(64.6); I) muscle pain, 57 (72.2); J) joint pain, 45 (57.0); K) abdominal pain, 47 (59.5); L) sore throat, 21 (26.6).

persons at day 7. Fever, headache, and pain (body/
muscle/bone/joint) were most frequently reported
on days 1–3, whereas abdominal pain was most frequently reported on days 3–5 (Figure 1).
We found substantial heterogeneity in reported
maximum intensity per symptom by participants.
We compiled the distribution of the maximum intensity reported by each person during the illness
period for 12 key symptoms on a 10-point scale (Figure 2). Symptoms with the highest median values
for maximum intensity (excluding those that did not
report the symptom at all) were malaise and fever

(8), body pain, headache, muscle pain, and weakness (7) (Figure 2).
We report the trajectories of symptom intensity
over the course of the illness for 6 symptoms (Figure
3); if the symptom was absent, an intensity of 0 was
assigned. For the study population as a whole, the intensity of individual symptoms followed a similar timing as the presence or absence of each symptom. However, there was substantial variation in the trajectories
of symptom intensity by participant (Figure 3).
We report correlations between the intensities of
individual symptoms and the hierarchical clustering

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 9, September 2020

2081

RESEARCH

dendrogram of symptom intensities (Figure 4). Pairwise correlations ranged from 0.12 (sore throat vs.
weakness) to 0.81 (body pain vs. muscle pain). Symptom intensity scores clustered into distinct groups
(i.e., constitutional [malaise and weakness], fever/
chills, headache/retroorbital pain, and musculoskeletal [body, muscle, bone, and joint pains]). Abdominal
pain and sore throat did not cluster with other symptoms in this analysis.
Symptom Intensity and Activity Change

A total of 48 (61%) participants reported a major
change in their daily activities on >1 days, 25 participants (32%) reported a minor change in daily
activities, and only 6 participants (8%) reported no
change in daily activities during their illness. On
the basis of logistic regression models analyzing
major activity change as a function of individual
symptom intensities, corrected for age and sex,
weakness had the strongest association with major
activity change (odds ratio 1.48, 95% CI 1.36–1.63),
followed by malaise (odds ratio 1.36, 95% CI 1.25–
1.48) (Table 2).
To assess the added value of measuring symptom intensity versus only symptom absence or

presence, we compared logistic regression models that used major activity change as the dependent variable (compared with minor or no activity
change as reference) and either the presence of a
symptom or the symptom intensity as the independent variable. The difference in the model (Δ-AIC)
was used to compare the 2 models, in which a positive Δ-AIC would favor the use of symptom intensity over presence/absence alone. Symptoms with
the greatest positive Δ-AIC were malaise (Δ-AIC
42.1), weakness (Δ-AIC 35.8), and fever (Δ-AIC
20.8) (Table 2). These data indicate that symptom
intensity is more valuable than symptom presence
or absence alone as a predictor of major activity
change during DENV infection.
Discussion
Symptoms reported most frequently by study participants were consistent with classical descriptions
of dengue illness, other cohort studies, and WHO
guidelines, as well as the key symptoms reported by
participants in our focus groups (19–22), although
a large fraction of participants reported less typical
gastrointestinal or respiratory symptoms. Participants enrolled as contact case-participants reported

Figure 3. Symptom intensities (scale 0–10) for 6 symptoms over the first 14 days of illness (0–13) for participants tested for
heterogeneity of dengue illness in community-based prospective study, Iquitos, Peru. A) Malaise; B) weakness; C) fever; D) headache;
E) body pain; F) abdominal pain. Box plots indicate trends for the study population as a whole. Dark horizontal lines indicate median,
upper limit of box indicates 75th percentile, lower limit of box indicates 25th percentile, upper whisker extends to the largest value <1.5
times the interquartile range; and lower whisker extends to the smallest value >1.5 times the interquartile range. Black dots indicate
individual scores. Colored lines indicate trajectories for a random sample of 10 individual participants.
2082
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Figure 4. Correlations of intensities of individual symptoms (379 surveys, 79 participants) and hierarchical clustering for participants
tested for heterogeneity of dengue illness in community-based prospective study, Iquitos, Peru. Tile colors indicate strength of
correlations. The height at which symptoms are linked in the dendrogram indicates how strongly they are related (lower height indicates
a closer link).

fewer symptoms, similar to the findings in cluster
investigations performed in Thailand (23). Some
of these persons might otherwise not have sought
medical attention. Only 1 (contact case-participant)
person reported no symptoms. This finding conflicts with evidence suggesting that only 12%–25%
of DENV infections are apparent (24,25). However,
it is likely that administering the IPR survey encouraged reporting of symptoms that would not have
been recalled in the context of a retrospective questionnaire, possibly explaining the relatively high

symptomatic to asymptomatic ratio in our sample.
We only collected data for persons who had a positive RT-PCR result (persons with only immunologic
evidence of seroconversion to DENV were not included). This limitation has been associated with a
higher frequency of symptoms (23).
Although most persons had mild dengue illness, our data demonstrate a range of intensity
levels for individual symptoms. The IPR survey
also enabled us to identify symptom groups within which daily intensities were highly correlated
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(r >0.70): constitutional (malaise and weakness),
fever (fever and chills), headache (headache and
retroorbital pain), and musculoskeletal pain (body,
muscle, bone, and joint pain).
Abdominal pain was reported by 59% of participants, but only 13% reported severe abdominal pain
(intensity >6). Abdominal pain followed a somewhat
different time course from and showed substantially
lower correlation with the symptom groups listed
above. This finding is consistent with a distinct physiologic mechanism for abdominal pain. It also supports guidelines classifying severe abdominal pain as
a warning sign, although few of our participants had
evidence of plasma leakage or severe bleeding.
Although our study population consisted primarily of persons with mild dengue illness, participants still reported a substantial impact of illness on
daily activities. Use of intensity scores for the major
symptoms substantially improved the assessment of
the effects of illness on daily activities when compared with use of symptom presence/absence alone.
Therefore, the ability of the IPR survey to capture
this aspect of heterogeneity in nonhospitalized persons with dengue could help improve assessment of
either beneficial or detrimental effects of interventions, as proposed by Thomas et al. (26). Moreover,
the causes of specific symptoms in dengue remain
poorly defined (19); instruments such as the IPR survey could potentially be used to explore these underlying mechanisms.
Recently, a group of experts proposed a data collection tool to capture the overall experience of a person with dengue based on how their symptoms affect
general wellness and functionality (26). The Dengue
Illness Index (DII) records the presence or absence of
symptoms daily. Our IPR survey has similarities to
the DII, but a major difference is that the IPR solicited
the assessment of the intensity of key symptoms of a
participant. Our data suggest that persons are able to
provide such an assessment and that intensity data
add information relevant to the overall assessment of
illness impact.
Thomas et al. (26) proposed a strategy for tabulating the DII to yield a single illness score. We did
not assign weights a priori for the different symptom intensities. Our data showing high correlations
within symptom groups suggests that each symptom
should not be given equal weight. We are exploring
approaches to express the symptom severity data
to a single or small number of the most informative
parameters (e.g., principal component analysis). Regardless of the specific approach used to score dengue symptom severity, it will be essential to define the
2084

relationships of severity score to other external measures of illness impact. In addition to data on change
in daily activities, described here, persons also provided data on movement (14) and on a health-related
quality of life survey, which we are incorporating into
future analyses.
Our findings should be interpreted in light of
several additional limitations. The IPR survey was
administered to participants by research staff using
a tablet-based application. Some choices in the design of the tablet-based survey addressed operational needs or preferences of the research team. These
considerations created some unanticipated challenges and required minor modifications to the tool
during the course of our study. For example, as a result of delays in receiving RT-PCR results or missed
follow-up assessments, it was difficult to accurately
assign a start and end date of some symptoms for
some persons. Imputation of missing data introduces error into our dataset that is difficult to quantify.
Our sample size is relatively small and homogenous
in host and viral populations. Our study was focused
on evaluation of persons with acute DENV infection
and did not include participants with nondengue febrile illnesses for comparison. Persons who participated in the focus groups or the main study are not
representative of the overall population of Iquitos
(e.g., greater time availability or willingness to engage with medical personnel). That said, the instrument development process, which engaged participants recently given a diagnosis of DENV infection
and clinical experts who reviewed the literature, resulted in a tool that assessed a wide range of symptoms and potential behavioral responses, which we
believe could be applied in other settings, although
Table 2. Effect of symptom intensity on reporting of major activity
change for participants tested for heterogeneity of dengue illness
in community-based prospective study, Iquitos, Peru
Symptom
Odds ratio (95% CI)*
Δ-AIC†
Malaise
1.36 (1.25–1.48)
42.1
Weakness
1.48 (1.36–1.63)
35.8
Fever
1.28 (1.19–1.38)
20.8
Abdominal
1.34 (1.22–1.48)
9.9
Body pain
1.32 (1.22–1.43)
9.1
Headache
1.27 (1.17–1.37)
9.0
Chills
1.31 (1.21–1.43)
3.3
Muscle pain
1.25 (1.15–1.35)
2.7
−0.0
Joint pain
1.23 (1.13–1.34)
−0.1
Retroorbital pain
1.11 (1.03–1.2)
−0.5
Sore throat
1.02 (0.87–1.18)
−1.4
Bone pain
1.24 (1.15–1.36)
*Shown is the increase in odds of reporting a major activity change when
symptom intensity is increased by 1 point for each of the 12 symptoms.
†Δ-AIC, difference in Akaike Information Criteria between models by using
binary symptom presence versus symptom intensity (0–10) as a predictor
of major activity change. A positive Δ-AIC favors the use of intensity over
presence of symptom alone.
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piloting the tool before use elsewhere is advisable.
Febrile illness surveillance was limited to selected
neighborhoods, and contacts were identified on the
basis of social proximity. Given the long-standing
interactions of the research team with the local population and the demographics of study participants,
we do not expect these considerations to have introduced major bias in our results.
Our data support the feasibility and rationale
of efforts to quantify dengue illness in future natural history and intervention studies. Our experience should be useful to guide development of
reliable and validated tools for this purpose. We
anticipate that the IPR survey could be adapted to
other formats, including self-administration by research subjects, and to other languages, but these
efforts would require modifications and further
validation. Further studies are needed to test our
results across other populations, to assign appropriate weights to individual symptom scores, and
to correlate with other biologic and epidemiologic
measures of disease impact.
Acknowledgments
We thank the residents of Iquitos for participating in this
study; Loreto Regional Health Department, including Hugo
Rodriguez-Ferruci, Christian Carey, Carlos Alvarez, Hernan
Silva, and Wilma Casanova Rojas, for providing support
and facilitating our work in Iquitos; the leadership of the
NAMRU-6 Virology and Emerging Infections Department
for providing institutional support, IRB guidance, and
supervising field staff; the NAMRU-6 IRB and Research
Administration Program for providing commentary and
advice; the NAMRU-6 Virology and Emerging Infections
Department field teams for providing daily support and
without whom the capture of acute-phase dengue cases
would not have been possible; the Movement team
(Alfonso Vizcarra, Jhonny C. López, Lorena Q. Flores, and
Esther J. Ríos) for providing assistance during data
collection; and Gabriela Vasquez de la Torre for providing
administrative support.
This study was supported by the US National Institutes
of Health/National Institute of Allergy and Infectious
Diseases (award no. P01AI098670 to T.W.S.), the Military
Infectious Disease Research Program (award no.
S0520_15_Li), and the US Department of Defense Global
Emerging Infections Systems Research Program (work unit
no. 847705.82000.25GB.B0016. A.R.R.-P. was supported by
the Wellcome Trust (#212712/Z/18/Z).
A.C.M., C.S., I.B., S.V., H.A., and R.D.H. were
employees of the United States government. This work
was prepared as part of their official duties. Title 17

U.S.C. 105 provides that copyright protection under this
title is not available for any work of the United States
Government. Title 17 U.S.C. 101 defines a US
Government work as work prepared by a military
service member or employee of the US Government as
part of that person’s official duties.

About the Author
Dr. Elson is a physician and research consultant working
for the University of California Davis, Davis, CA. His
research interests include clinical and epidemiologic
aspects of arboviral diseases, including dengue and Zika,
and vectorborne disease control.
References
1.

2.
3.

4.

5.
6.

7.

8.

9.

10.
11.
12.

World Health Organization. Dengue: guidelines for
diagnosis, treatment, prevention and control, 2009. Geneva:
The Organization [cited 2019 Mar 14]. http://www.ncbi.nlm.
nih.gov/books/NBK143157
Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue.
N Engl J Med. 2012;366:1423–32. https://doi.org/10.1056/
NEJMra1110265
Martínez-Vega RA, Carrasquila G, Luna E,
Ramos-Castañeda J. ADE and dengue vaccination.
Vaccine. 2017;35:3910–2. https://doi.org/10.1016/
j.vaccine.2017.06.004
World Health Organization Special Programme for Research
and Training in Tropical Diseases. Dengue: guidelines for
diagnosis, treatment, prevention, and control, 2009 [cited
2020 Jun 3]. https://apps.who.int/iris/handle/10665/44188
World Health Organization. Dengue haemorrhagic fever:
diagnosis, treatment, prevention, and control. 2nd ed.
Geneva: The Organization; 1997.
Srikiatkhachorn A, Rothman AL, Gibbons RV,
Sittisombut N, Malasit P, Ennis FA, et al. Dengue: how best
to classify it. Clin Infect Dis. 2011;53:563–7. https://doi.org/
10.1093/cid/cir451
Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA,
Vazquez-Prokopec GM, Astete H, et al. House-to-house
human movement drives dengue virus transmission. Proc
Natl Acad Sci U S A. 2013;110:994–9. https://doi.org/
10.1073/pnas.1213349110
Morrison AC, Minnick SL, Rocha C, Forshey BM, Stoddard
ST, Getis A, et al. Epidemiology of dengue virus in Iquitos,
Peru 1999 to 2005: interepidemic and epidemic patterns of
transmission. PLoS Negl Trop Dis. 2010;4:e670.
https://doi.org/10.1371/journal.pntd.0000670
Morrison AC, Gray K, Getis A, Astete H, Sihuincha M,
Focks D, et al. Temporal and geographic patterns of Aedes
aegypti (Diptera: Culicidae) production in Iquitos, Peru.
J Med Entomol. 2004;41:1123–42. https://doi.org/
10.1603/0022-2585-41.6.1123
Peru National Institute of Statistics and Informatics INEI
[in Spanish] [cited 2019 Mar 15]. https://www.inei.gob.pe/
estadisticas/indice-tematico/poblacion-y-vivienda
Ministry of Health Peru. Comprehensive Health Insurance
[in Spanish] [cited 2019 Mar 15]. http://www.sis.gob.pe/
portal/estadisticas/resumen.html
Reiner RC Jr, Stoddard ST, Forshey BM, King AA,
Ellis AM, Lloyd AL, et al. Time-varying, serotype-specific
force of infection of dengue virus. Proc Natl Acad Sci

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 9, September 2020

2085

RESEARCH

13.

14.

15.

16.
17.
18.
19.
20.

21.

22.

23.

24.

25.

26.

U S A. 2014;111:E2694–702. https://doi.org/10.1073/
pnas.1314933111
Ministry of Health Peru. Situation for the health situation
analysis, 2019, week 19 [in Spanish]. [cited 2019 Jun 6].
https://www.dge.gob.pe/portal/index.php?option=
com_content&view=article&id=664
Schaber KL, Paz-Soldan VA, Morrison AC, Elson WHD,
Rothman AL, Mores CN, et al. Dengue illness impacts daily
human mobility patterns in Iquitos, Peru. PLoS Negl Trop
Dis. 2019;13:e0007756. https://doi.org/10.1371/
journal.pntd.0007756
Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A,
Gibbons RV, et al. A new quantitative RT-PCR method for
sensitive detection of dengue virus in serum samples.
J Virol Methods. 2008;153:1–6. https://doi.org/10.1016/
j.jviromet.2008.06.023
CommCare by Dimagi. Data collection app [cited 2019 Apr
5]. https://www.dimagi.com/commcare
R Core Team. R: a language and environment for statistical
computing. Vienna: R Foundation for Statistical Computing,
2013 [cited 2020 Jun 3]. http://www.R-project.org
Kolde R. pheatmap: pretty heatmaps, 2019. R package
version 1.0.12 [cited 2020 Jun 3]. https://CRAN.R-project.org
Wilder-Smith A, Ooi E-E, Horstick O, Wills B. Dengue.
Lancet. 2019;393:350–63. https://doi.org/10.1016/
S0140-6736(18)32560-1
Potts JA, Rothman AL. Clinical and laboratory features that
distinguish dengue from other febrile illnesses in endemic
populations. Trop Med Int Health. 2008;13:1328–40.
https://doi.org/10.1111/j.1365-3156.2008.02151.x
Cobra C, Rigau-Pérez JG, Kuno G, Vorndam V. Symptoms
of dengue fever in relation to host immunologic response
and virus serotype, Puerto Rico, 1990–1991. Am J Epidemiol.
1995;142:1204–11. https://doi.org/10.1093/oxfordjournals.
aje.a117579
Halsey ES, Baldeviano GC, Edgel KA, Vilcarromero S,
Sihuincha M, Lescano AG. Symptoms and immune
markers in Plasmodium/dengue virus co-infection compared
with mono-infection with ether in Peru. PLoS Negl
Trop Dis. 2016;10:e0004646. https://doi.org/10.1371/
journal.pntd.0004646
Yoon I-K, Srikiatkhachorn A, Hermann L, Buddhari D,
Scott TW, Jarman RG, et al. Characteristics of mild dengue
virus infection in Thai children. Am J Trop Med Hyg.
2013;89:1081–7. https://doi.org/10.4269/ajtmh.13-0424
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW,
Moyes CL, et al. The global distribution and burden of
dengue. Nature. 2013;496:504–7. https://doi.org/10.1038/
nature12060
Stanaway JD, Shepard DS, Undurraga EA, Halasa YA,
Coffeng LE, Brady OJ, et al. The global burden of dengue:
an analysis from the Global Burden of Disease Study 2013.
Lancet Infect Dis. 2016;16:712–23. https://doi.org/10.1016/
S1473-3099(16)00026-8
Thomas SJ, Agulto L, Hendrickx K, Erpicum M,
Tomashek KM, Cassetti MC, et al. Dengue illness index: a
tool to characterize the subjective dengue illness
experience. PLoS Negl Trop Dis. 2018;12:e0006593.
https://doi.org/10.1371/journal.pntd.0006593

EID Podcast:
Antibiotic Resistance
and Fungus
Dr. David Denning, President
of the Global Action Fund
for Fungal Infections and
an infectious diseases clinician,
discusses antimicrobial
resistance and fungus.

Visit our website to listen:
https://www2c.cdc.gov/podcasts/player.asp?f=8645104

Address for correspondence: Valerie A. Paz-Soldán, Global
Community Health and Behavioral Sciences Department, Tulane
University School of Public Health and Tropical Medicine,
1440 Canal St, Ste 2200, New Orleans, LA 70112, USA; email:
vpazsold@tulane.edu
2086

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 9, September 2020

